Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is one of the most prevalent bacterial infections in humans. More than one third of the world's population is currently infected by Mtb and close to two million TB-associated deaths are reported annually (World Health Organization, 2006) . Because of the ability of Mtb to persist in infected hosts for prolonged periods of time, treatment of TB requires the administration of a multi-drug regimen for six to nine months. The lengthy course of anti-TB treatment sometimes leads to noncompliance in patients, who often relapse with TB caused by Mtb strains with enhanced drug resistance (Bradford & Daley, 1998) .
In recent years, there has been a rising trend in the occurrence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB); these strains are characterized as highly virulent Mtb strains that are nonresponsive to most front-line anti-TB drugs and to many second-line therapeutic compounds. The death rate of patients contracting MDR-TB or XDR-TB is much higher than that of patients infected by regular Mtb, especially in patients with compromised immune systems. The appearance of these newly emerging Mtb strains has severely weakened the effectiveness of the present anti-TB therapy in developing countries, many of which are already facing mounting numbers of cases of HIV/AIDS patients in their populations (World Health Organization, 2006) .
As a member of the TB structural genomics consortium, we are actively pursuing the structural determination of Mtb proteins with critical biological functions. Structural biology has a successful track record as a drug-development tool. It is our hope that the structures of these essential Mtb proteins will shed light on the biological processes in which these Mtb proteins participate and may one day lead to new anti-TB therapies.
In this paper, we report the molecular cloning, protein purification and preliminary X-ray crystallographic analysis of Rv2247, a subunit of acyl-CoA carboxylase (ACCD6). Carboxylases are involved in the biosynthesis of fatty acids that are key components of the Mtb cell wall (Cronan & Waldrop, 2002; Takayama et al., 2005; Tong, 2005) . Mtb possesses six acyl-CoA carboxylase subunits (ACCD1-6). Three of them, ACCD4-6, are essential genes for the survival of Mtb on minimal medium ( Fig. 1 ; Sassetti et al., 2001) . The Mtb cell wall is heavily decorated by Mtb-specific fatty acids (e.g. mycolic acids) which are likely to contribute to the ability of Mtb to evade the host immune response, resist antibiotics and persist in immune cells such as macrophages. The subunits carry out the only substrate-specific step during fatty-acid chain elongation catalyzed by acyl-CoA carboxylases. Therefore, the presence of multiple ACCD genes in the Mtb genome is thought to be linked to the wide variety of lipids found in the cell wall of Mtb Holton et al., 2006; Lin et al., 2006; Takayama et al., 2005) . Mtb ACCD6 has been shown to be able to use both propionyl-CoA and acetyl-CoA as substrates, with a threefold higher efficiency in carboxylation of the latter (Daniel et al., 2007) . Based on ACCD6 being part of the fatty-acid synthesis (FAS) II locus, it was hypothesized that Mtb ACCD6 may produce the malonyl-CoA molecules that are used to synthesize meromycolic acid by the catalytic components of FAS II. Kurth and coworkers reported that ACCD6 is essential in M. smegmatis, a common laboratory relative of Mtb (Kurth et al., 2009) . Consequently, ACCDs are attractive targets for the design of novel anti-TB therapeutics. An inhibitor, NCI-172033, has been identified to be effective against ACCD6 at 8 mM in vitro and has been shown to exhibit rather widespectrum anti-mycobacterial activity (Kurth et al., 2009) . At low concentrations ($25 mM) this compound is bacteriostatic, whereas at 100 mM it is clearly bacteriocidal. While the crystal structure of Mtb ACCD5 is known (Lin et al., 2006) , there is currently no deposition in the Protein Data Bank (PDB) for the molecular structure of Mtb ACCD6, which is a promising novel anti-TB target.
Materials and methods
2.1. Cloning, expression and purification of recombinant Mtb ACCD6
The Rv2247 gene was amplified by the polymerase chain reaction (PCR) using a bacterial artificial chromosome (BAC) genomic library received from L'Institut Pasteur (Brosch et al., 1998; Gordon et al., 1999) . Sequence alignment of the Mtb ACCD4-6 -carboxylases. The secondary structures corresponding to Mtb ACCD5 (PDB entry 2a7s; Lin et al., 2006) are drawn at the top of the sequence alignment. Helices, -strands and turns are represented by coils, arrows and 'T's. Conserved residues are highlighted with a red background, whereas residues with similar chemical properties are coloured red. Sequence alignment was performed using the program ClustalW ( Thompson et al., 1994) and the figure was generated with the program ESPript (Gouet et al., 1999).
Gateway cloning system (Invitrogen) are 2247f, ggg aca agt ttg tac aaa aaa gca ggc tcg ggc agc gaa aat ctg tat ttt cag ggc agc ggc ATG ACA ATC ATG GCC CCC GAG G (where bold letters indicate the recombinant tobaco etch virus protease cleavage site and the upper case letters represent the Rv2247-coding region), and 2247r, gg gac cac ttt gta caa gaa agc tgg gtc ctc gag TTA CAG CGG GAT GTT CTT GTG GCG.
The full open reading frame encoding residues 1-473 of Mtb Rv2247 was gel-purified and inserted into the pDONR221 plasmid (Invitrogen) to generate an entry clone plasmid pDONR2247. Subsequently, the coding region of Rv2247 in pDONR2247 was cloned into the expression plasmid pDEST-15 (Invitrogen) with an aminoterminal glutathione S-transferase (GST) fusion partner. The coding sequence of Rv2247 in this expression plasmid (pGST-2247) was verified by DNA-sequencing analysis (DNA Core Facility, Department of Biochemistry, University of Alberta, Canada).
BL21 arabinose-inducible Escherichia coli cells transformed with pGST-2247 were incubated at 310 K in a shaker until the OD reached 0.6. 0.2% d-arabinose was then added to the culture to induce the production of recombinant Rv2247.
For recombinant Rv2247 protein purification, the cell pellet from a 2 l culture was collected via centrifugation at $12 000g (max.) for 30 min and resuspended in 40 ml lysis buffer consisting of 20 mM Tris pH 7.5, Complete protease-inhibitor cocktail (Roche), 100 mM NaCl, 50 mM KCl, 1 mM DTT, 1 mM PMSF. The cells were lysed by one round of freeze-thawing followed by ultrasonication. The cell lysate was cleared by centrifugation at 30 000g (max.) for 30 min and the supernatant was loaded onto a 5 ml GSTrap glutathione Sepharose column (GE Healthcare) pre-equilibrated with buffer A (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM -mercaptoethanol). Recombinant GST-Rv2247 fusion protein was eluted using buffer B [50 mM Tris-HCl pH 8.5, 10 mM glutathione (GSH), 0.02% NaN 3 ]. Recombinant tobacco etch virus protease (AcTEV, Invitrogen) was used to proteolytically release the GST tag from the GST-Rv2247 fusion protein. After overnight dialysis to remove GSH, the digested protein mixture was again loaded onto a GSTrap column. The flowthrough fractions that contained liberated Rv2247 were concentrated and exchanged into buffer C (10 mM Tris-HCl pH 7.5, 50 mM NaCl, 50 mM KCl, 5 mM MgCl 2 , 5 mM -mercaptoethanol, 0.5 mM DTT, 0.02% NaN 3 ) before being loaded onto a size-exclusion column (Sephadex G-75). The eluted fractions were sampled for the presence of purified Rv2247 and the peak fractions were pooled and concentrated to $5 mg ml À1 using an Amicon Ultra filtration unit (30 kDa cutoff, Millipore); the purity of the protein (>95%) was confirmed by 15% SDS-PAGE (data not shown).
Crystallization
Crystallization conditions were manually screened using the hanging-drop method and commercial sparse-matrix-based solution sets (Index HT, Crystal Screen and Crystal Screen 2; Hampton Research). Two different crystal forms of Mtb ACCD6 of similar diffraction quality were obtained by mixing equal volumes (0.5-1 ml) of ACCD6 solution (20 mg ml À1 ) and reservoir solution and letting the mixture equilibrate over 1 ml reservoir solution at 297 K. Form I crystals were obtained using the reservoir solution 2.8 M sodium formate pH 7.5 and form II crystals were obtained using 0.1 M Tris pH 8.5, 0.2 M ammonium sulfate, 23% PEG 3350. Both of these crystals grew to dimensions of $50 Â 100 Â 200 mm in 2-3 d (Fig. 2) .
Data collection
As sodium formate at concentrations of 2.8 M and higher is a proven cryoprotectant, form I Rv2247 crystals were flash-cooled by directly submerging looped crystals in liquid nitrogen, whereas form II crystals were cooled in liquid nitrogen after passing the crystals through a drop of reservoir solution supplemented with 30% glycerol as a cryoprotectant. Native X-ray diffraction data sets were collected on a Rigaku R-AXIS IV ++ rotating-anode X-ray generator and at the Canadian Light Source (beamline CMCF1). Raw data were indexed, integrated and scaled using the HKL-2000 program suite (Otwinowski & Minor, 1997) . The cutoff resolution was chosen on the basis of the signal-to-noise ratio (>2.0) and the value of R merge (<1.0).
Results
We have cloned, expressed, purified and crystallized Mtb Rv2247, a subunit of acyl-CoA carboxyltransferase (ACCD6). X-ray diffraction data were collected both at the home source and on a synchrotron beamline. Form I and II crystals diffracted to 2.9 and 2.5 Å resolution, respectively, at the synchrotron-radiation source (Fig. 3) . 
